ArticleEuropean journal of nuclear medicine and molecular imaging2019
Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for
Open access · hybridAbstract readComparative Study
In one paragraph
Article in European journal of nuclear medicine and molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
7.9field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 111 citations in OpenAlex.
- Predicting tumour and organ dose in α-radiopharmaceutical therapy: aEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Glycoprotein Mucin 13 Expression as a Theranostic Target in Colorectal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Dipicolinic acid (DPA)-based chelators for zirconium-89 PET imaging applications.Bioorganic & medicinal chemistry letters · 2026Article
- New Synthetic Strategies Toward DFO*: Enhanced Yield and Purity of a Key Chelator forPharmaceuticals (Basel, Switzerland) · 2026Article
- Enhanced Tumor-to-Background Contrast with [Pharmaceuticals (Basel, Switzerland) · 2026Article
- Synthesis and Evaluation of D8W, an Octadentate Desferrioxamine Analogue with Enhanced Water Solubility Designed forMolecular pharmaceutics · 2026Article
- Is Thiourea the Weak Link? An Investigation of the In Vitro and In Vivo Destabilization of [ACS bio & med chem Au · 2026Article
- Emerging ImmunoPET probes for precision cancer immunotherapy: molecular targets and translational applications.Frontiers in oncology · 2026Review
- Article
- From Desferrioxamine B Umpolung to an Enantiopure Bifunctional Chelator forChemistry (Weinheim an der Bergstrasse, Germany) · 2025Article
- Development of a toxin-selective immunotracer for in vivo detection of Clostridioides difficile infection by immunoPET.EJNMMI radiopharmacy and chemistry · 2025Article
- Article
- Radiation protection considerations with [EJNMMI research · 2025Article
- Isopeptidic Desferrioxamine Analogues: The Role of Hydroxamate Spacing for Chelation of ZrChemMedChem · 2025Article
- Biodistribution ofACS omega · 2025Article
- A first-in-class dual-chelator theranostic agent designed for use with imaging-therapy radiometal pairs of different elements.Chemical science · 2024Article
- Bifunctional octadentate pseudopeptides as Zirconium-89 chelators for immuno-PET applications.EJNMMI radiopharmacy and chemistry · 2024Article
- Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Assessment of Novel Mesothelin-Specific Human Antibody Domain VH-Fc Fusion Proteins-Based PET Agents.ACS omega · 2023Article
- Comparative in vivo biodistribution of cells labelled with [EJNMMI research · 2023Article
Corrections and comments
- Commented on by
Authors and funding
17 authors at 3 institutions in 4 countries.
René RaavéDepartment of Radiology and Nuclear Medicine, Radboudumc, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0002-5234-0707
Gerwin SandkerDepartment of Radiology and Nuclear Medicine, Radboudumc, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
Pierre AdumeauInstitut de Chimie Moléculaire de l'Université de Bourgogne, UMR 6302, CNRS, Université Bourgogne Franche-Comté, 9 avenue A. Savary, 21078, Dijon Cedex, France.
Christian Borch JacobsenGlobal Research Technologies, Novo Nordisk A/S, Novo Nordisk Park, DK-2760, Måløv, Denmark.
Floriane ManginInstitut de Chimie Moléculaire de l'Université de Bourgogne, UMR 6302, CNRS, Université Bourgogne Franche-Comté, 9 avenue A. Savary, 21078, Dijon Cedex, France.
Michel MeyerInstitut de Chimie Moléculaire de l'Université de Bourgogne, UMR 6302, CNRS, Université Bourgogne Franche-Comté, 9 avenue A. Savary, 21078, Dijon Cedex, France.
Mathieu MoreauInstitut de Chimie Moléculaire de l'Université de Bourgogne, UMR 6302, CNRS, Université Bourgogne Franche-Comté, 9 avenue A. Savary, 21078, Dijon Cedex, France.
Claire BernhardInstitut de Chimie Moléculaire de l'Université de Bourgogne, UMR 6302, CNRS, Université Bourgogne Franche-Comté, 9 avenue A. Savary, 21078, Dijon Cedex, France.
Laurène Da CostaInstitut de Chimie Moléculaire de l'Université de Bourgogne, UMR 6302, CNRS, Université Bourgogne Franche-Comté, 9 avenue A. Savary, 21078, Dijon Cedex, France.
Adrien DuboisInstitut de Chimie Moléculaire de l'Université de Bourgogne, UMR 6302, CNRS, Université Bourgogne Franche-Comté, 9 avenue A. Savary, 21078, Dijon Cedex, France.
Victor GoncalvesInstitut de Chimie Moléculaire de l'Université de Bourgogne, UMR 6302, CNRS, Université Bourgogne Franche-Comté, 9 avenue A. Savary, 21078, Dijon Cedex, France.
Magnus GustafssonGlobal Research Technologies, Novo Nordisk A/S, Novo Nordisk Park, DK-2760, Måløv, Denmark.
Mark RijpkemaDepartment of Radiology and Nuclear Medicine, Radboudumc, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
Otto BoermanDepartment of Radiology and Nuclear Medicine, Radboudumc, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
Jean-Claude ChambronInstitut de Chimie Moléculaire de l'Université de Bourgogne, UMR 6302, CNRS, Université Bourgogne Franche-Comté, 9 avenue A. Savary, 21078, Dijon Cedex, France. jcchambron@unistra.fr.
Sandra HeskampDepartment of Radiology and Nuclear Medicine, Radboudumc, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands. Sandra.heskamp@radboudumc.nl.
Franck DenatInstitut de Chimie Moléculaire de l'Université de Bourgogne, UMR 6302, CNRS, Université Bourgogne Franche-Comté, 9 avenue A. Savary, 21078, Dijon Cedex, France. franck.denat@u-bourgogne.fr.
Centre National de la Recherche Scientifique · FRRadboud University Nijmegen · NLNovo Nordisk (Denmark) · DK
Funding
Innovative Medicines Initiative 116106KWF Kankerbestrijding 10099Nederlandse Organisatie voor Wetenschappelijk Onderzoek 91617039
Abstract
purposeCurrently, the most commonly used chelator for labelling antibodies with
methodsThe stability of
results
conclusion
Indexed as
AnimalsCell Line, TumorCell Transformation, NeoplasticDeferoxamineFemaleHumansMicePositron Emission Tomography Computed TomographyRadioisotopesTissue DistributionZirconiumDeferoxamineRadioisotopesZirconiumZirconium-8989ZrDFODFO*DFOcyclo*immunoPETMonoclonal antibodies
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.